Bleharski Joshua 4

What Happened
Joshua Bleharski, Chief Financial Officer of IDEAYA Biosciences (IDYA), was granted a derivative award covering 170,000 shares, reported on Form 4 with a transaction date of 2026-01-30. The award is reported at $0.00 (code A — grant/award), meaning no cash purchase was made; this is a compensation grant, not an open-market buy.

Key Details

• Transaction date: 2026-01-30; reported filing date: 2026-02-02 (filed within the standard Form 4 two-business-day window).
• Reported price: $0.00 (award/derivative).
• Shares granted: 170,000 (derivative security).
• Shares owned after transaction: Not specified in the filing.
• Vesting (per footnote F1): 25% vests on the first anniversary measured from the Vesting Commencement Date (January 1, 2026), then 1/48th of the total shares vest monthly thereafter; 100% vests on the 4th anniversary (fully vested by Jan 1, 2030).
• No 10b5-1 plan, tax-withholding, or late-filing flags noted in the Form 4.

Context
This is a standard executive compensation grant (derivative award such as stock options or RSUs) intended to align management incentives and retain the CFO over multiple years. Because it’s an award (not an open-market purchase), it shouldn’t be interpreted as a direct personal cash investment signal.